Because seizures associated with Lennox-Gastaut syndrome (LGS) are difficult to control, many treatments are often used in combination to attempt to reduce seizures.
BANZEL (rufinamide) is a prescription medication approved for the adjunctive treatment of seizures associated with LGS in children 4 years and older and adults.
Reductions in total seizures include tonic-atonic
The efficacy of BANZEL was evaluated as an add-on treatment in a 12-week clinical study of patients 4 years and older and adults diagnosed with LGS. The study included 2 patient groups, one in which BANZEL was added to their current therapy and another in which a placebo (a sugar pill with no medication in it) was added to their current therapy. The median* reduction in total seizures for the BANZEL group was 32.7% versus 11.7% for the placebo group. This study also measured the change in frequency of tonic-atonic (drop) seizures. For the BANZEL group there was a median reduction of 42.5% in the frequency of this type of seizure versus a median increase of 1.4% in the placebo group.
In the same study, the parents or guardians of the LGS patients evaluated the patients’ seizure severity. More parents or guardians of the BANZEL patients reported improvements in seizure severity than those in the placebo group — 53.4% versus 30.6%.
*Median means that in a list of all the results from every person in the study, this number falls right in the middle, with an equal number of people who did better and people who did worse.
Because everyone is unique, different people may have different results with BANZEL. If you have any questions about this data, please contact your healthcare provider.
Ask your healthcare provider about adding BANZEL to an existing treatment.
NEXT: Taking BANZEL